CEO Discusses Product Offerings and Corporate Strategy with PRBroadcast.com in Online Interview.

DUBLIN, Ohio -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that the Company is presently featured in an online interview at www.PrBroadcast.com. CEO David Bupp discusses the Company's biomedical product offerings, development activities as well as other matters impacting the future performance of the company.

The Neoprobe Corporation interview is available at http://www.PRBroadcast.com. To access the interview, click on "Join Now/Log In" in the upper right corner. After providing your name, e-mail address, and creating a password, click on the "Send" button at the top of the page. This will register you and send you back to the PRBroadcast.com home page. You may access any CEO Interview or Company name by "trading symbol" (NEOP) or company name located in the upper left portion of the PRBroadcast.com web page.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(TM) and RIGScan(R) CR. Neoprobe's recently formed subsidiary, CIRA Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

About PRBroadcast.com

PRBroadcast.com presents detailed interviews with CEO's, Company CFO's and Analysts which provides publicly traded companies with production services and distribution of their corporate messages in streaming video/audio format. Your corporate message is delivered firsthand to all major newswires, institutional and private investors, venture capitalists and buy and sell analysts, all at the click of a mouse. Using our state of the art webcasting services, PRBroadcast.com can feature and host CEO interviews, business updates, earning conference calls, analyst presentations, product launches and other special announcements directly to your audience's desktop, at minimal cost compared to video or telephone conferencing. PRBroadcast.com will provide public companies with the means and ability to reach far into the investment community with a direct message to shareholders and potential investors, through our streaming media technology, active databases of institutional and individual investors, analysts, brokerage firms and large affiliate network while providing the most impact for the communications dollar.

For a complete corporate profile on Neoprobe Corporation. Please visit www.PRBroadcast.com or contact the company directly at : 614.793.7500

Statements in this interview, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its product, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.